SXTPNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTPW
60 DEGREES PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.83−0.03 (-3.29%)
Close on Oct 19, 2026
- Market cap
- $2.20M
- P/E (TTM)
- –
- Dividend yield
- –
60 DEGREES PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q3 24 | Q2 24 | Q1 24 | Q3 23 | Q2 23 | Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Product Revenues - net of Discounts and Rebates | $135.29K | $124.97K | – | $51.19K | $59.53K | – | 100.0% | +164.3% |
| Service Revenues | $0 | $0 | $10.79K | – | – | – | 0.0% | – |
| Product Revenues net of Discounts and Rebates | – | – | $105.67K | – | – | $17.17K | – | – |
By region
From the segment and revenue-disaggregation notes of 60 Degrees Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.